Polycomb segment myeloid malignancies

Blood

Volumn 119, Issue 5, 2012, Pages 1097-1098

  Saunthararajah, Yogen ^a   Maciejewski, Jaroslaw ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; DNA METHYLTRANSFERASE 1; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE H3; POLYCOMB GROUP PROTEIN; PROTEIN ASXL1; PROTEIN JARID2; PROTEIN SUZ12; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CHROMOSOME 7; CHROMOSOME DELETION; CHROMOSOME LOSS; CHRONIC MYELOMONOCYTIC LEUKEMIA; GENE INACTIVATION; GENE MUTATION; HISTONE METHYLATION; HUMAN; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; NOTE; PATHOGENESIS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTOSIS; TREATMENT RESPONSE;

EID: 84856605920     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-12-391268     Document Type: Note

References (14)

1. Score J, Hidalgo-Curtis C, Jones AV, et al. Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/ myeloproliferative neoplasms. Blood. 2012;119(5):1208-1213.
2. Kroeze LI, Nikoloski G, da Silva-Coelho P, et al. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. Blood. 2012;119(5): 1318-1319.
3. Nikoloski G, Langemeijer SM, Kuiper RP, et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet. 2010; 42(8):665-667.
4. Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010;42(8):722-726.
5. Makishima H, Jankowska AM, Tiu RV, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010;24(10):1799-1804.
6. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. NEngl J Med. 2011;364(26):2496-2506.
7. Guglielmelli P, Biamonte F, Score J, et al. EZH2 mutational status predicts poor survival in myelofibrosis. Blood. 2011;118(19):5227-5234.
8. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011;19(1):138-152.
9. Negrotto S, Ng KP, Jankowska AM, et al. CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors [published online ahead of print August 12, 2011]. Leukemia. doi:10.1038/leu.2011.207.
10. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.NEngl J Med. 2004;351(7):657- 667.
11. Hu Z, Gu X, Baraoidan K, et al. RUNX1 regulates corepressor interactions of PU. 1. Blood. 2011;117(24): 6498-508.
12. Kirstetter P, Schuster MB, Bereshchenko O, et al. Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells. Cancer Cell. 2008;13(4): 299-310. (Pubitemid 351446194)
13. Traina F, Jankowska AM, Visconte V, et al. Impact of molecular mutations on treatment response to hypomethylating agents inMDS[abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):461.
14. Ng KP, Ebrahem Q, Negrotto S, et al. p53 independent epigenetic- differentiation treatment in xenotransplant models of acute myeloid leukemia. Leukemia. 2011;25(11): 1739-1750.